Finn
MLYS Biotechnology · Clinical stage · Hypertension · Single asset · Thesis updated November 8, 2026

One drug and a hard FDA date

01 Running thesis

A hard FDA clock and major financing

Mineralys is a regulatory story with a clear date. The company submitted its NDA for lorundrostat in hypertension in December 2025. The FDA accepted it and set a PDUFA target action date of December 22, 2026.

The bull case rests on strong data and launch readiness. Lorundrostat has already shown positive results in uncontrolled and resistant hypertension, as well as chronic kidney disease. The company recently fully hired its field sales team and holds $624.7 million in cash, providing a runway into 2028.

The bear case centers on execution and new costs. Mineralys owns one main drug and has never launched a product. A new $500 million debt facility introduces financial leverage, with core intellectual property pledged as collateral. Furthermore, a newly disclosed potential 100 percent tariff on imported drug products could severely impact commercial margins if enacted.

The next big watch item is the FDA decision. Before then, investors should look for updates on payer strategy, supply chain mitigations for the tariff risk, and whether the kidney disease indication needs a larger trial.

Nov 2026→Mineralys confirmed its field sales team is fully hired and reported $624.7 million in cash. The company also newly disclosed a potential 100 percent tariff risk on imported drug products.
Aug 2026▲Mineralys announced a $200 million upfront payment to repurchase royalty obligations for lorundrostat. The company also completed a $150 million equity offering and entered a $500 million term loan facility.
May 2026→The Q1 2026 filing kept the main thesis in place. It repeated that the lorundrostat NDA was accepted and that the FDA target action date is December 22, 2026.
Mar 2026▲The 2025 annual filing confirmed the hypertension NDA submission and FDA acceptance, which gave investors a firm review date. The same filing also showed that the OSA trial missed its primary endpoint, cutting off a near-term expansion path.
Nov 2025→Mineralys narrowed its NDA timing to late 2025 or early 2026. At that time, a U.S. government shutdown was a timing risk for FDA review.
Aug 2025▲Explore-CKD met its endpoints, including blood pressure and albuminuria. That gave lorundrostat its first clear clinical support beyond the main hypertension program.
May 2025▲Launch-HTN and Advance-HTN both produced positive topline results in uncontrolled or resistant hypertension. Mineralys also raised about $188.7 million in net proceeds, improving its funding position.
02 Business model

Cash now, launch later

Mineralys does not make money from drug sales today. It spends cash to run studies, prepare filings, and build for a possible commercial launch. Its value comes entirely from the chance that lorundrostat becomes an approved medicine.

Lorundrostat was in-licensed from Mitsubishi Tanabe. Mineralys recently paid $200 million upfront to repurchase future royalty obligations, though it may still owe up to $100 million if certain commercial milestones are met.

The company funded operations through its IPO, equity financings, and a $500 million term loan facility. It ended the third quarter of 2026 with $624.7 million in cash and investments. This capital provides strong backing heading into a possible commercial launch, but the debt adds risk since core intellectual property is pledged as collateral.

Commercial success will depend on more than FDA approval. Doctors must prescribe the drug, insurers must cover it, and the company must manage supply chain costs, including a potential 100 percent tariff on imported materials.

03 Product portfolio

Lorundrostat, by use case

Growth engine

Lorundrostat for uncontrolled hypertension

This is the lead use case and the center of the NDA. The FDA target action date is December 22, 2026.

Growth engine

Lorundrostat for resistant hypertension

This is part of the same high blood pressure filing path. It targets patients whose blood pressure stays high even with other medicines.

Option

Lorundrostat for chronic kidney disease

The Phase 2 Explore-CKD trial met its endpoints, including blood pressure and albuminuria. The open question is whether regulators need a dedicated Phase 3 trial.

Option

Lorundrostat for obstructive sleep apnea

The Phase 2 Explore-OSA trial missed its primary endpoint. This makes OSA a weak near-term value driver, even though blood pressure changes and safety were favorable.

04 Business segments

No sales mix yet

Research and development operations100%modest
Commercial product revenue0%flat

Mineralys reported one operating segment and no commercial product revenue in its Q3 2026 updates. All current effort is dedicated to research, development, and launch preparations.

05 Risk factors

What can break

FDA rejects or delays lorundrostat

High impact · Medium odds

The NDA has been accepted, but the drug is not approved yet. The FDA could ask for more safety data, more analysis, labeling limits, or a new study. Since lorundrostat is the main asset, a negative decision would hit the whole company.

We watchFDA action on or before the December 22, 2026 PDUFA target date.

One-drug concentration

High impact · High odds

Mineralys is built around lorundrostat. If the drug fails in hypertension or gets a narrow label, there is no approved second product to offset the damage. The OSA miss already showed the risk of leaning on one molecule for many uses.

We watchAny FDA label language, safety warning, or company update that narrows the hypertension opportunity.

Debt collateral risk

High impact · Low odds

The company entered a $500 million term loan and pledged substantially all its assets, including intellectual property, as collateral. If Mineralys defaults on this loan, lenders could foreclose on the core assets that drive the business.

We watchUpdates on cash flow, loan covenant compliance, and commercial progress that impacts the ability to service debt.

Import tariffs crush margins

High impact · Medium odds

The company relies on imported drug products. A newly disclosed risk of up to 100 percent tariffs on these imports could drastically increase the cost of goods sold. If imposed, this would squeeze cash flow during the critical launch phase.

We watchTrade policy updates and company announcements regarding domestic manufacturing shifts.

Pricing and coverage fall short

High impact · Medium odds

High blood pressure is a large market, but many older medicines are cheap. Lorundrostat must win a clear place in treatment for insurers and doctors. Approval alone may not equal strong sales.

We watchEarly payer coverage, launch price, and management guidance on target patient groups.
06 Quick answers

In one breath

What does Mineralys Therapeutics do?

Mineralys is developing lorundrostat, an oral drug that blocks aldosterone production. Aldosterone is a hormone that can raise blood pressure and affect heart and kidney health.

When is the key FDA date for MLYS?

The FDA set a PDUFA target action date of December 22, 2026 for lorundrostat in hypertension. That is the main near-term catalyst for the stock.

Does Mineralys have revenue?

No. Mineralys is still clinical stage and has not commercialized a product, so it has no product revenue today.

Why did the OSA trial matter?

OSA, or obstructive sleep apnea, was a possible expansion area for lorundrostat. The Phase 2 trial missed its primary endpoint, so it is no longer a near-term driver of the investment case.

07 Research standards

Sources and research notes

This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.

Thesis reviewed
November 8, 2026
Score data
November 15, 2026
Reviewed by
Shivam Bharuka
  1. Mineralys Therapeutics Q3 2026 Form 10-Q
  2. Mineralys Therapeutics Q2 2026 Form 10-Q
  3. Mineralys Therapeutics 2025 Form 10-K
08 Explore the industry

Comparable Biotechnology companies

Companies near Mineralys Therapeutics, Inc. in Finn's Biotechnology industry ranking.

Get started with Finn today